Genextest LLC is an official distributor of Myriad in Estonia and Russia.
Myriad offers an array of genetic tests, prognostic tests, and personalized medicine tests to healthcare providers to help them assess a patient’s increased cancer risk, disease aggressiveness, optimize efficacy of chemotherapy and identify patients’ most suitable for therapy.
EndoPredict® is the only test that answers the following three important clinical questions…

  • Can chemotherapy be avoided? (individual risk at 10 years)
  • What is the absolute benefit from chemotherapy? (individual chemotherapy benefit)
  • Can endocrine therapy be stopped after 5 years? (individual risk up to 15 years)

… to optimize treatment for breast cancer patients.

EndoPredict patient leaflet_ENG.pdf

EndoPredict_HCP_Premenopausal brochure_ENG.pdf


Paris provides new information about your cancer that no other test can. The Prolaris test can determine just how unique and aggressive your prostate cancer truly is. Your Prolaris Score provides individualized information about your specific cancer to help you and your physician develop the appropriate treatment plan.

Prolaris provides answers to your most pressing questions

• What is the risk of my cancer spreading outside of the prostate?

• What is my risk to die from my prostate cancer?

• How should my cancer be treated - Am I a candidate for active surveillance? - Should I consider active treatment?



  • myChoice CDx is the first and only FDA-approved tumor test that determines homologous recombination deficiency status by detecting BRCA1 and BRCA2 (sequencing and large rearrangement) variants and assessing genomic instability using three critical biomarkers: loss of heterozygosity, telomeric allelic imbalance and large-scale state transitions.

    myChoice CDx PLUS identifies patients that are most likely to benefit from PARP inhibitors. It is the only commercially available tumor test that has been designed to detect large rearrangements which account for 5% of all ovarian cancer mutations.

    MyChoice CDx Plus Patient Brochure_02_22_ENG.pdf

    MyChoice CDx Plus_HCP_Safe decisions brochure_ENG.pdf

  • BRACAnalysis CDx® is an FDA-approved laboratory developed test for BRCA1 and BRCA2 intended to inform patient management related to the PARP inhibitors, Lynparza® (olaparib) and Zejula® (niraparib).

    BRACAnalysis CDx (Europe) Technical Specifications.pdf


  • Myriad myRisk® Hereditary Cancer is a 35-gene panel that helps to determine a patient’s risk by evaluating a number of hereditary cancer syndromes, with focus on eight primary cancer sites.

    MyRisk Plus HCP Brochure_05_22_EN.pdf

  • RiskScore® is a clinically validated algorithm that predicts a woman’s remaining 5-year and lifetime risk of developing breast cancer at no additional cost (as the additional option for MyRisk test).